177Lu-capromab pendetide (CYT 500)

Most commonly used forms of PRRT are Lutetium 177 labelled DOTATATE (Lutathera, Advanced Accelerator Applications, a Novartis company) which was recently approved by U.S. Food and Drug Administration (FDA) and Yttrium 90 labelled DOTATATE. Traveling while undergoing PRRT should be discussed with the patient by the clinical care team and nuclear medicine/nuclear radiology team prior to treatment to avoid any unwanted surprises. Patients can arrange their schedules accordingly if they are well informed about this process ahead of time.